Latest News
Immunovant, Inc.
- Immunovant, Inc. Estimates – NASDAQ:IMVT
- Immunovant to report Q2 2026 financial results and business update on Nov 9
- Form 4 Roivant Sciences Ltd.: Eric Venker (President & Immunovant CEO) For: 30 September
- Investigation launched into Immunovant officers for possible self-dealing harming shareholders
- Immunovant (IMVT) Slides Toward $31.62 as Shares Retreat Nearly 5% - PSAR Stop
- Form 4 Immunovant Inc For: 5 October By Investing.com
- Immunovant details Phase 3 PROPEL trial of imeroprubart in generalised myasthenia gravis
- Immunovant Shares Results from Proof-of-Concept Study of Imeroprubart in Cutaneous Lupus
- Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)
- Immunovant's FcRn Antibody IMVT-1402 Misses Primary Endpoint in Cutaneous Lupus
- Immunovant ends skin-lupus programme after trial misses primary goal
- Immunovant drops IMVT-1402 in cutaneous lupus after proof-of-concept miss
Headlines from the last 30 days, linking to the original publishers. See all market news →